Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Follow-Up Questions
Psyence Biomedical Ltd (PBM)'in P/E oranı nedir?
Psyence Biomedical Ltd 'in P/E oranı 2.3826 'dir
Psyence Biomedical Ltd 'in CEO'su kimdir?
Mr. Marc Balkin 2021 'den beri şirketle birlikte olan Psyence Biomedical Ltd 'in Chief Executive Officer 'ıdır.
PBM hissesinin fiyat performansı nasıl?
PBM 'in mevcut fiyatı $2.71 'dir, son işlem günde 1.09% decreased etti.
Psyence Biomedical Ltd için ana iş temaları veya sektörler nelerdir?
Psyence Biomedical Ltd Biotechnology endüstrisine ait ve sektör Health Care 'dir
